MX2024002467A - Terapias combinadas. - Google Patents
Terapias combinadas.Info
- Publication number
- MX2024002467A MX2024002467A MX2024002467A MX2024002467A MX2024002467A MX 2024002467 A MX2024002467 A MX 2024002467A MX 2024002467 A MX2024002467 A MX 2024002467A MX 2024002467 A MX2024002467 A MX 2024002467A MX 2024002467 A MX2024002467 A MX 2024002467A
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapies
- actrii
- treatment
- combined
- glp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163238068P | 2021-08-27 | 2021-08-27 | |
| US202263301012P | 2022-01-19 | 2022-01-19 | |
| US202263333351P | 2022-04-21 | 2022-04-21 | |
| PCT/US2022/075545 WO2023028606A1 (en) | 2021-08-27 | 2022-08-26 | Combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002467A true MX2024002467A (es) | 2024-05-20 |
Family
ID=83897998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002467A MX2024002467A (es) | 2021-08-27 | 2022-08-26 | Terapias combinadas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240325530A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4392137A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024532619A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099142A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118488853A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022332306A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3229355A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310919A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024002467A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202323296A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023028606A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4121078A4 (en) | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| EP4466288A4 (en) * | 2022-01-19 | 2026-02-25 | Versanis Bio Inc | ACTRII ANTIBODY-BASED TREATMENTS |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| EP4577301A1 (en) | 2022-08-26 | 2025-07-02 | Versanis Bio, Inc. | Actrii antibody fixed unit dose treatments |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| IL326224A (en) | 2023-07-31 | 2026-03-01 | Sixpeaks Bio Ag | Antibody conjugates and fusion proteins |
| WO2025106773A1 (en) * | 2023-11-17 | 2025-05-22 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent |
| IL330385A (en) * | 2023-12-29 | 2026-08-01 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Antibody-polypeptide conjugate and its pharmaceutical use |
| WO2025147483A1 (en) * | 2024-01-02 | 2025-07-10 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii chimeras |
| WO2025183966A1 (en) | 2024-02-28 | 2025-09-04 | Versanis Bio, Inc. | Actrii antibodies with extended half life |
| WO2025217521A1 (en) * | 2024-04-12 | 2025-10-16 | Jnana Therapeutics Inc. | Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist |
| WO2025247309A1 (zh) * | 2024-05-31 | 2025-12-04 | 上海齐鲁制药研究中心有限公司 | 融合蛋白分子及其应用 |
| WO2026128614A1 (en) * | 2024-12-10 | 2026-06-18 | Supercede Therapeutics, Inc. | Activin receptor type ii inhibitors for preventing or treating obesity and related disorders |
| EP4785960A1 (en) | 2025-01-31 | 2026-08-05 | SixPeaks Bio AG | Glp-1 antibody conjugates |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2655877T3 (es) | 2009-04-27 | 2018-02-22 | Novartis Ag | Composiciones y métodos para aumentar el crecimiento muscular |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| WO2018129395A1 (en) * | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
-
2022
- 2022-08-26 EP EP22797198.3A patent/EP4392137A1/en active Pending
- 2022-08-26 TW TW111132340A patent/TW202323296A/zh unknown
- 2022-08-26 CA CA3229355A patent/CA3229355A1/en active Pending
- 2022-08-26 IL IL310919A patent/IL310919A/en unknown
- 2022-08-26 KR KR1020247010022A patent/KR20240099142A/ko active Pending
- 2022-08-26 AU AU2022332306A patent/AU2022332306A1/en active Pending
- 2022-08-26 CN CN202280066217.5A patent/CN118488853A/zh active Pending
- 2022-08-26 MX MX2024002467A patent/MX2024002467A/es unknown
- 2022-08-26 WO PCT/US2022/075545 patent/WO2023028606A1/en not_active Ceased
- 2022-08-26 JP JP2024537306A patent/JP2024532619A/ja active Pending
-
2024
- 2024-02-26 US US18/587,617 patent/US20240325530A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240325530A1 (en) | 2024-10-03 |
| EP4392137A1 (en) | 2024-07-03 |
| WO2023028606A1 (en) | 2023-03-02 |
| AU2022332306A1 (en) | 2024-02-29 |
| CA3229355A1 (en) | 2023-03-02 |
| IL310919A (en) | 2024-04-01 |
| CN118488853A (zh) | 2024-08-13 |
| TW202323296A (zh) | 2023-06-16 |
| KR20240099142A (ko) | 2024-06-28 |
| JP2024532619A (ja) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008330A (es) | Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos. | |
| TW200730168A (en) | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | |
| BR0010138A (pt) | Moduladores de receptores de glucocorticóides | |
| MA39061A1 (fr) | Modulateurs d'aplnr et leurs utilisations | |
| NZ774980A (en) | Trem2 stabilizing antibodies | |
| EP4344706A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| TN2017000148A1 (en) | Co-agonists of the glucagon and glp-1 receptors | |
| MX2009006339A (es) | Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide. | |
| BR112016000804A2 (pt) | Método para tratar hemorragia, choque e lesão cerebral | |
| Pandi-Perumal et al. | Could agomelatine be the ideal antidepressant? | |
| MEP27308A (en) | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual | |
| BR112012006035A2 (pt) | epratuzumab para uso no tratamento de uma doença autoimune ou inflamatória, e, kit | |
| MA32233B1 (fr) | Régime de dosage pour un agoniste sélectif du récepteur s1p<sb>1</sb> | |
| WO2008153632A3 (en) | Compositions and methods for treating obesity and related disorders | |
| BR112013030939A2 (pt) | derivado de indazol e pirrolopiridina e uso farmacêutico do mesmo | |
| MX2021013427A (es) | Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33. | |
| EA200701705A1 (ru) | Антагонисты рецепторы глюкагона, получение и терапевтическое применение | |
| CY1110922T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| UY31622A1 (es) | Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2 | |
| AU2010236734A8 (en) | 5-HT4 receptor agonist compounds for treatment of cognitive disorders | |
| EP4596044A3 (en) | Combination therapy of gpr119 agonists and dpp-4 inhibitors | |
| O’Connor et al. | The effects of mGlu7 receptor modulation in behavioural models sensitive to antidepressant action in two mouse strains | |
| MX2024002845A (es) | Nuevos peptidos como agonistas potentes y selectivos del receptor de gip. | |
| BRPI0720114A8 (pt) | Uso de um antagonista beta-adrenérgico e antagonista ou agonista parcial de 5-ht1a combinados, método para tratar caquexia, e, antagonista beta-adrenérgico e antagonista ou agonista parcial de 5-ht1a combinados | |
| DK1951659T3 (da) | Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf |